Ophthalmological Infectious Diseases

As mentioned earlier above, emerging infectious diseases became life threatening because of globalization. Now these find their way even in Ophthalmology causing infections to eye. This session describes the infections of eye in detail and how they can be diagnosed and treated with the recent advancements of the research field

Sub-Tracks

• Retinitis and Chorioretinitis
• Retinal Vasculitis
• Optic Neuropathy
• Ocular Immunology
• Trachoma and Conjuctivitis

Market Analysis: The global ophthalmological infectious-disease therapeutics market (eye-infection treatment) is currently estimated at about USD 8.16 billion in 2025 and is projected to reach USD 9.83 billion by 2030 (CAGR ~3.8%), driven by steady volumes of bacterial, viral, and fungal eye infections, expanding OTC access to anti-infective drops, and incremental innovation in sustained-release delivery and combination formulas. Within this, conjunctivitis remains the largest revenue pool, at ~USD 4.53 billion in 2025 and tracking toward ~USD 5.54 billion by 2030 (CAGR ~4.1%); the viral conjunctivitis drugs niche is expected to rise from ~USD 375 million in 2025 to ~USD 531 million by 2032 (CAGR ~5.1%), reflecting periodic outbreaks and heightened hygiene awareness. By geography, mature markets continue to anchor absolute dollars while emerging Asia adds the fastest unit growth; for example, the U.S. alone is expected to take conjunctivitis treatment revenues to ~USD 1.6 billion by 2030 (CAGR ~3.8%) on stable prescribing and aging demographics. Looking at product classes, ophthalmic anti-infectives as a category are on track to reach roughly USD 6.5 billion by 2033, indicating durable demand for topical antibiotics/antivirals even amid generic erosion, while enabling technologies such as ophthalmic drug-delivery systems are forecast to expand to ~USD 23.36 billion by 2030 (CAGR ~6.6% from mid-decade), supporting longer-acting inserts and improved adherence that lift branded value capture. Altogether, these trajectories imply a mid-single-digit growth profile for infectious ophthalmology through 2030+, with upside tied to launches that shorten dosing cycles or address resistance patterns, and downside chiefly from patent cliffs and continued genericization of first-line antibiotics.

For More Details : https://microbiology-infectiousdiseases.peersalleyconferences.com/tracks/ophthalmological-infectious-diseases